Command Palette

Search for a command to run...

Preprint WatchMildOctober 14th, 2026

Normative transcriptomic clues to thalamic developmental vulnerability in C9orf72-FTLD

So, I.; Bouzigues, A.; Ferry-Bolder, E.; Cullen, E.; Russell, L.; Foster, P.; Farley, S.; Convery, R.; van Swieten, J. C.; Jiskoot, L. C.; Seelaar, H.; Galimberti, D.; Vandenberghe, R.; Laforce, R.; Bruffaerts, R.; Bertoux, M.; Lebouvier, T.; Solje, E.; Levin, J.; di Fede, G.; Thompson, A.; Le Ber, I.; Lara Migliaccio, R.; Kortvelyessy, P.; Schroeter, M. L.; Logroscino, G.; Otto, M.; Uzelac, Z.; Illan-Gala, I.; Kruger, J.; Nacmias, B.; Gerhard, A.; Langheinrich, T.; Ducharme, S.; Santana, I.; Tartaglia, C.; Masellis, M.; de Mendonca, A.; Rowe, J.; Graff, C.; Moreno, F.; Synofzik, M.; Borroni,

Normative transcriptomic patterns indicate thalamic developmental vulnerability in C9orf72-associated frontotemporal lobar degeneration, proposing a neurodevelopmental contribution to regional degeneration.

Mild contradiction

1 prior failure

One documented clinical failure (Phase 1 or 2) overlaps with the claimed mechanism.

The preprint proposes that regional vulnerability in C9orf72 disease is partly set during development rather than arising solely from adult repeat expansion toxicity. Claidex holds one C9orf72 failure, wve-004-c9orf72-als-ftd-phase1-2-translational-mismatch, in which target engagement did not convert into clinical benefit. A developmental component would help explain that pattern, because lowering a toxic species in adulthood cannot reverse vulnerability that is already structurally established. The practical implication is that trials of repeat-targeting agents should measure regional structural baselines and treat them as effect modifiers rather than as nuisance covariates.

Abstract excerpt

C9orf72 encodes a protein that is important for both typical neurodevelopment and homeostatic processes across the lifespan. Pathogenic C9orf72 repeat expansions constitute the most common genetic cause of frontotemporal lobar degeneration (FTLD). Collectively, preclinical models and clinical neuroimaging studies have observed smaller thalamic volumes in C9orf72-associated FTLD, including in asymptomatic young adult C9orf72 repeat expansion carriers across 18 to 30 years old, supportive of potential neurodevelopmental origins. However, it is unknown whether asymptomatic young adult C9orf72 expansion carriers demonstrate volume differences in specific thalamic nuclei, as reported in older asymptomatic carriers and symptomatic patients; if so, normative transcriptomic patterns could reveal relevant neurodevelopmental and/or FTLD-related neurodegenerative processes. This study investigated volumetric MRI differences of the thalamic nuclei in asymptomatic young adult C9orf72 expansion carriers compared to non-carriers, and examined spatial associations with normative thalamic transcriptomics from 8 weeks post-conception through middle age. Young adult C9orf72 expansion carriers (n=72) and non-carriers (n=48) were enrolled in the Frontotemporal Dementia Prevention Initiative across Europe, Canada, and the USA (ages: 18-30 years; sex: 57% female). Spatial associations between young adult thalamic nuclei volumes and normative transcriptomics from the Allen Human Brain Atlas were examined using complementary data-driven and hypothesis-driven approaches. Spatial expression patterns of transcripts of interest were characterized across prenatal and postnatal neurodevelopment using BrainSpan data. Smaller volumes of the pulvinar, mediodorsal, and lateral nuclei were observed in young adult C9orf72 expansion carriers compared to non-carriers. These nuclei showed higher normative expression of transcripts involved concurrently in neurodevelopmental and C9orf72-associated FTLD neurodegenerative processes (including lysosomal, autophagic, and small GTPase functions), and lower normative expression of CALB1, a marker of prenatal human thalamic development. Normative expression of CALB2 (another human thalamic development marker) yielded positive correlations with C9orf72 across prenatal development to adulthood. These findings identify candidate transcripts that may provide insight into the molecular architecture leading to smaller thalamic nuclei volumes in C9orf72-associated FTLD.

Matching Claidex post-mortems

1 of 1 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.